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Summary
Objective: To analyze the effects of exogenously added glucose (Glc), glucosamine (GlcN) and glucosamine sulfate (GS) on the intracellular
UDP-hexoses (UDP-Hex), UDP-N-acetylhexosamines (UDP-HexN) and UDP-glucuronic acid (UDP-GlcA) levels in bovine primary
chondrocytes.
Methods: Chondrocytes were incubated with different concentrations of Glc, GlcN and GS either in high- or low-glucose DMEM for up to
120 min to analyze the intracellular levels of UDP-Hex, UDP-GlcA and UDP-HexN by a reversed-phase high-performance liquid chromatog-
raphyeelectrospray ionization mass spectrometry analysis. Glycosaminoglycan (GAG) synthesis rate and aggrecan mRNA expression levels
were quantiﬁed using 35S-sulfate incorporation assay and quantitative real-time RT-PCR, respectively. The cells were cultivated for 2 days or 8
days before UDP-sugar analysis.
Results: Levels of UDP-HexN and UDP-GlcA were unchanged at 10 mM concentration of GS in low-glucose DMEM, while addition of 1 mM
GlcN or GS in low-glucose DMEM for 10 min increased UDP-HexN level. The highest intracellular level of UDP-HexN was reached at 30 min
after addition of 1 mM GS to the cells. The intracellular contents of UDP-HexN and UDP-GlcA related to UDP-Hex were higher after prolonged
cultivation of chondrocytes for 8 days compared with 2-day-old cultures. Aggrecan mRNA expression and GAG synthesis remained at control
level after the cells were treated with 10, 100 mM or 1 mM of GS for 24 h.
Conclusion: Physiologically relevant level of GS could not increase the intracellular UDP-HexN and UDP-GlcA levels in bovine primary chon-
drocyte, while longer-time culture itself appeared to increase the intracellular UDP-HexN and UDP-GlcA levels.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
Intracellular nucleotide-activated sugars are required for cel-
lular energy metabolism and the assembly of several cellular
structures. They serve as substrates for glycosyltrans-
ferases that are involved in the synthesis of carbohydrate
structures of numerous glycoproteins, glycolipids and gly-
cosaminoglycan (GAG) chains of proteoglycans. Glucos-
amine (GlcN) is a basic structural unit of chondroitin sulfate
(CS) and hyaluronan of cartilage proteoglycan aggregates.
Therefore, oral administrations of GlcN, glucosamine sulfate
(GS) or CS, either alone or in combination1e5, are widely
used as nutraceuticals to treat osteoarthritis (OA), and they
are also prescribed as drugs in some European countries.
It has been suggested that besides having a symptom-
modifying effect they are also structure-modifying agents4,
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Received 7 December 2006; revision accepted 6 January 2007.77even though a number of recent clinical trials have not uni-
formly shown that either GlcN or GS would be more effective
than placebo in the treatment of OA6e10.
It has been reported that GlcN or GS stimulates CS syn-
thesis in a rat model11 and in human OA chondrocytes12.
Glucosamine also appeared to inhibit degradation of carti-
lage aggrecan13, and inﬂammatory responses14. Although
these results have raised promises of the disease-modify-
ing effects of GlcN or GS, the cellular mechanisms behind
these proposed effects are not clear. The bioavailability
of GlcN and GS has been conﬁrmed. However, the level
of the sugar reaching the cartilage after oral administration
is very low, approximately 10 mM15. Even if there would
be a substantial uptake of GlcN in the digestive system
its availability is remarkably declined during the passage
by the portal system and through the liver. Therefore, it
has been questioned whether the low level of GlcN
achieved in serum and synovial ﬂuid after oral admini-
stration would be sufﬁcient to affect GAG synthesis in
chondrocytes15.
Glucosamine is produced intracellularly from glucose
(Glc), and it is one of the basic sugar structures used for
the synthesis of CS through conversion of fructose-6-
phosphate to glucosamine-6-phosphate (GlcN-6-P) by the
enzyme glutamine:fructose-6-phosphate aminotransferase
(GFAT, Fig. 1). GlcN-6-P is then rapidly converted into the3
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CoA:glucosamine-6-phosphate N-acetyltransferase (Fig. 1).
Exogenous GlcN or GS supplemented to the cultured
cells can enter this metabolic pathway via conversion into
GlcN-6-P.
N-Acetylglucosamine-6-phosphate is further converted
via N-acetylglucosamine-1-phosphate into UDP-GlcNAc,
and by epimerase into UDP-GalNAc. These nucleotide-
activated sugars, together with UDP-glucuronic acid (UDP-
GlcA), are exploited in the assembly of GAG chains
(Fig. 1). CS polysaccharide chain is composed of GlcA
and GalNAc, and keratan sulfate of galactose and
GlcNAc, while hyaluronan consists of GlcA and GlcNAc
(Fig. 1). It has been shown that supplemental GlcN can af-
fect cellular metabolism. In adipocytes, high exogenous
concentration (2 mM) of GlcN increased UDP-GlcNAc
levels at 14e18 min of treatment by increasing the levels
of glucose-6-phosphate or GlcN-6-P, while GlcN concen-
tration lower than 250 mM elevated the levels of UDP-
GlcNAc without increasing GlcN-6-P16. However, the
report did not show how the levels of UDP-GlcA and
UDP-GalNAc behaved or if GlcN at concentrations avail-
able after oral administration of GS have effect on the
cultivated cells.
In the present study, we used a reversed-phase high-per-
formance liquid chromatographyeelectrospray ionization
mass spectrometry (RP-HPLC/ESI-MS) method to analyze
the intracellular levels of UDP-hexoses (UDP-Hex, UDP-
Glc is the predominant form, however, may contain other
UDP-hexoses), UDP-GlcA, and UDP-hexosamines (UDP-
HexN, the pool of the UDP-GlcNAc and UDP-GalNAc) in
bovine primary chondrocytes after treatment with different
concentrations of Glc, GlcN and GS (including physiologi-
cally obtainable concentrations) following 2- and 8-day-
long cell cultures. Aggrecan mRNA expression and GAG
synthesis were also analyzed after the cells were treated
with different concentrations of GS for 24 h.
Fig. 1. The biosynthetic pathway of CS from glucose or glucos-
amine. UDP-Glc, UDP-glucose; Acetyl-CoA, acetyl-coenzymeA;
UDP-GlcNAc, UDP-N-acetylglucosamine; UDP-GalNAc, UDP-N-
acetylgalactosamine; GFAT, glutamine:fructose-6-phosphate ami-
notransferase; UDP-GlcA, UDP-glucuronic acid.Materials and methods
MATERIALS
Glucosamine hydrochloride was purchased from Sigma
(Steinheim, Germany, purity 99%), and sodium sulfate
from Merck (Darmstadt, Germany). Glucosamine hydro-
chloride and sodium sulfate salts were dissolved in
DMEM (sulfate concentration 0.81 mM, Euroclone, Pero,
Italy) at known concentrations, thus, the added GS con-
tained glucosamine, sulfate and chloride (but not covalently
N-linked glucosamine sulfate) in the dissociated forms.
Eurozol reagent was obtained from Euroclone, and [35S]
sulfate from New England Nuclear (Boston, MA, USA). Di-
methylhexylamine (DMHA) was purchased from Aldrich
(Milwaukee, WI, USA). N,N-Methyladenosine 50-triphos-
phate (AppCp), uridine 50-diphosphoglucose (UDP-Glc), uri-
dine 50-diphosphoglucuronic acid (UDP-GlcA) and uridine
50-diphospho-N-acetylglucosamine (UDP-GlcNAc) were
from Sigma Chemical Co. (St. Louis, MO, USA). Methanol
was HPLC grade and purchased from Labscan Ltd. (Dublin,
Ireland). Water was puriﬁed and deionized in a Milli-Q puri-
ﬁcation system from Millipore (Bedford, MA, USA).
PREPARATION OF ISOLATED CHONDROCYTE
Isolated primary chondrocytes were obtained from the ar-
ticular cartilage of bovine (estimated age of animals 13e22
months) femoral condyles by collagenase digestion17. After
digestion, the isolated chondrocytes were washed twice
with PBS, counted and plated in monolayer cultures at
5 105 chondrocyte per well of a 6-well plate. Cultures
were maintained in DMEM culture medium (1.0 g of glu-
cose/l, or 5.0 g of glucose/l) supplemented with 10% FCS
(PAA, Linz, Austria), penicillin (100 U/ml, Euroclone), strep-
tomycin (100 mg/ml, Euroclone) and 2 mM L-glutamine
(PAA), and maintained in a humidiﬁed incubator at 37C
with 5% CO2 atmosphere. The primary chondrocytes were
cultured for 2 or 8 days.
TREATMENT OF CHONDROCYTE CULTURES WITH GLUCOSE,
GLUCOSAMINE OR GLUCOSAMINE SULFATE
In the ﬁrst set of experiment, Glc, GlcN and GS at 10,
100 mM and 1 mM concentration were added to the regular
medium described above, and 1.4 ml of this medium was
changed into the cell cultures after the initial 2- or 8-day-
long cultivation on the 6-well plates. The cells were then
cultured for 10 min in an incubator before collection of the
samples for UDP-sugar analysis. The cells were also
treated with 1 mM of GS in high-glucose (5.0 g/l) DMEM
media for 10 min. Both experiments were repeated with
cells obtained from three animals.
In the next experiment, the cells were treated with 10 mM
and 1 mM concentrations of GS in low-glucose DMEM me-
dium for 10, 20, 30, 60 and 120 min to investigate how GS
affects the UDP-HexN and UDP-GlcA levels in chondro-
cytes. The experiment was repeated with cells from two an-
imals. Maximal responses were observed 30e60 min after
the addition of exogenous GS. Therefore, we performed ad-
ditional experiments in 10 mM concentration of GS in low-
glucose DMEM for 30 and 60 min. These experiments
were repeated with cells from nine animals.
The cells were also treated with 10, 100 mM and 1 mM
concentrations of GS for 24 h after prior 8-day-long cell cul-
tures to analyze the GAG synthesis and aggrecan mRNA
expression. These experiments were repeated with cells
from 12 animals.
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After treatment, the plates were placed on ice, and the
mixture of the cells and medium were collected in a 1.5 ml
microcentrifuge tubes. The tubes were centrifuged at
380 g (2000 rpm) for 5 min at 4C, and the pellets were
washed once with ice-cold 1 PBS. The cell pellet was ex-
tracted with 300 ml of cold acetonitrile with a subsequent ad-
dition of 200 ml of cold H2O within 2 min. The samples were
mixed with vortex, and then centrifuged at 16,060 g
(13,000 rpm) for 1 min at 4C. The supernatant was trans-
ferred to a new tube, and stored frozen at 20C for later
analysis. The acetonitrile was vaporized using vacuum cen-
trifuge and dissolved by vortex mixing in 150 ml of Milli-Q
water containing 5 mM AppCp as an internal standard prior
to analysis.
The sugar nucleotides were analyzed by RP-HPLC/ESI-
MS measurement. Brieﬂy, measurements were carried out
with a Finnigan Surveyor MS Pump and a Finnigan Sur-
veyor autosampler (Thermo Electron Corporation, San
Jose, CA, USA) with a 50 ml loop. The RP column used
was Phenomenex Gemini C18 (50 2.00 mm, particle
size 5 mm), ﬂow rate 200 ml/min, and injection volume
45 ml. Eluents were 20 mM DMHA formate (pH adjusted to
7.0 with formic acid, A), and 80% methanol containing
2 mM DMHA formate (B). The HPLC gradient was 2 min
of eluent A, 0e100% of eluent B in 3 min, 100% eluent B
for 4 min, and subsequent stabilization of the column with
eluent A for 4 min.
A Finnigan LTQ quadrupole ion trap mass spectrometer
(Thermo Electron Corporation, San Jose, CA, USA) equip-
ped with an electrospray ionization source was used, and
the instrument was operated on a negative ion mode. The
quantitation was based on multiple reaction (MRM) of the
most intense fragment ions. The followed ions were m/z
579/ 403 for UDP-GlcA, m/z 606/ 385 for UDP-
GlcNAc, m/z 565/ 323 for UDP-Glc, and m/z 504/ 406
for the internal standard AppCp. To create a standard
curve, the sugar nucleotide standards were diluted in Milli-
Q water over a concentration range of 0.5e10 mM for
UDP-GlcA and UDP-Glc, and 0.5e30 mM for UDP-GlcNAc,
and the chromatographic peak area ratios of the standards
and the internal standard were plotted against the concen-
trations of standards. The values in pmols were normalized
against DNA content of the samples.
The RP-HPLC/ESI-MS measurements used in the pres-
ent study could not distinguish between the different UDP-
Hex, or UDP-HexN because they have the same mass.
Thus, UDP-Hex refers to the pool of UDP-Glc, UDP-man-
nose and UDP-galactose, and UDP-HexN to the pool of
UDP-GlcNAc, and UDP-GalNAc.
RNA EXTRACTION AND REAL-TIME QUANTITATIVE RT-PCR
Total RNA extractions from bovine primary chondrocytes
were performed with EUROzol according to the manufactur-
er’s instruction after the cells were treated with different
concentrations of GS for 24 h following an 8-day period of
cell culture. The concentration of total RNA was determined
by spectrophotometric measurement at 260 nm.
Total RNA (10 mg) was treated with recombinant DNase I
(Ambion, Houston, TX, USA). Purity and integrity of RNA
was determined by spectrophotometry, and by gel electro-
phoresis before reverse transcription (RT). For 20 ml of RT
reaction, 0.5 mg of DNA-free total RNA from each group,
random primers, and ABsolute MAX QRTase Blend re-
verse transcriptase (ABsolute MAX QRTase kit, ABgene,Epsom, Surrey, UK) were used. The RT reaction was incu-
bated for 60 min at 42C, for 10 min at 75C, and for 2 min
at 4C in an MJ Research PTC-200 device (Waltham, MA,
USA). The cDNA was stored at 20C prior to use. The
cDNA was checked with gel electrophoresis before real-
time quantitative RT-PCR performance.
The levels of mRNA encoding for bovine aggrecan and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were quantiﬁed with real-time quantitative RT-PCR employ-
ing Mx3000P Real-Time PCR System (Stratagene, La
Jolla, CA, USA). The 25 ml of RT-PCR reaction contained
4 ml of cDNA, 12.5 ml of ABsolute QPCR SYBR Green
Mix, 0.5 ml of ROX reference dye, and 300 nM (GAPDH)
or 100 nM (aggrecan) forward and reverse primers. The
conditions of real-time RT-PCR was a single cycle of en-
zyme activation for 15 min at 95C, followed by 40 ampliﬁ-
cation cycles for 30 s at 95C denaturation, 1 min at 60C
annealing, and 30 s at 72C extension. Sequences of the
primers used in real-time RT-PCR were the following:
GAPDH forward primer: 50 TTC AAC GGC ACA GTC
AAG G 30, reverse primer: 50 ACA TAC TCA GCA CCA
GCA TCA C 30; aggrecan forward primer: 50 CAC TGT
TAC CGC CAC TTC CC 30, reverse primer: 50 GAC ATC
GTT CCA CTC GCC CT 30. The experiments were repeated
in samples from 12 animals.
35S-SULFATE INCORPORATION ANALYSIS
On the eighth cultivation day, the media were changed
with the one containing the different concentrations (0,
10 mM and 1 mM) of GS. 35S-sulfate (5 mCi/ml) was added
into each well of the 6-well plates, then the cultures were in-
cubated in a humidiﬁed incubator at 37C with 5% CO2 for
24 h. The supernatants were collected, and the amounts of
incorporated and free 35S-sulfate were analyzed as in our
previous study17. The experiment was performed with the
cells from 12 individual animals. The increase of sulfate
concentration in the medium caused by the addition of GS
was taken into account when the results were calculated
on a molar basis.
STATISTICAL ANALYSIS
The statistical signiﬁcance of the differences between the
control and treated groups were tested using non-paramet-
ric Wilcoxon Signed Ranks Test. A difference was consid-
ered statistically signiﬁcant when P-value was less than
0.05.
Results
EFFECTS OF GLUCOSAMINE, GLUCOSAMINE SULFATE
AND GLUCOSE ON INTRACELLULAR UDP-HEXOSES, UDP-
GLUCURONIC ACID AND UDP-N-ACETYLHEXOSAMINES
The effect of GlcN and GS on the intracellular UDP-sugar
levels at different concentrations was examined ﬁrst, both in
low- and high-glucose DMEM. The content of UDP-HexN
increased after 10 min of treatment at 1 mM concentrations
of GlcN (Fig. 2A) and GS (Fig. 2B) in low-glucose DMEM,
while the content of UDP-GlcA slightly decreased. Similar
changes were found in the ratio of UDP-HexN/UDP-Hex
and UDP-GlcA/UDP-Hex. However, no changes were
found at 10 and 100 mM concentrations of GlcN and GS
10 min after addition of the sugars (Fig. 2A, B). In high-
glucose DMEM, 1 mM GS did not affect the UDP-sugar
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mary chondrocytes were treated with 0, 10, 100 mM and 1 mM of glucosamine (GlcN) (A) and glucosamine sulfate (GS) in low-glucose DMEM
(B) for 10 min. The experiments were performed with cell cultures from three different animals.levels (data not shown). Glucose at 10, 100 mM and 1 mM
concentrations in low-glucose DMEM did not change
UDP-sugar levels (data not shown). Consequently, the fol-
lowing experiments were performed only in low-glucose
DMEM.
The levels of UDP-sugars during a time course of 2 h
were also studied. The highest level of UDP-HexN was
reached at 30 min after the addition of 1 mM GS treatment
(Fig. 3A). Although the absolute level of UDP-HexN ap-
peared to decrease after 30 min, UDP-Hex level also drop-
ped so that the ratio of UDP-HexN/UDP-Hex tended to
increase during the time course of the treatment in 1 mM
GS treatment. However, the level of UDP-GlcA still re-
mained at the control levels. Previously, the maximum level
of GlcN in serum was found to be in the range of
1.9e11.5 mM after oral administration of GS18. Therefore,
we treated the chondrocytes with 10 mM concentration of
GS in low-glucose DMEM for 30 and 60 min to investigate
whether exogenous, physiologically relevant concentration
of GS could increase the intracellular UDP-HexN and
UDP-GlcA levels. The experiment was repeated with chon-
drocyte cultures from nine animals. However, no changes
were noticed in the contents of UDP-HexN and UDP-GlcA
after different time points (Fig. 3B).
Primary chondrocytes are often cultivated for several
days before experimental procedures which may affect
the metabolic balance of the cells. Thus, we investigated
whether the duration of the culture time has impact on the
responses of chondrocytes to GS. The cells were treated
with 10 mM and 1 mM concentrations of GS for 30 min after
prior 2- and 8-day-long cell cultures. After the 2-day culture
period, the content of UDP-HexN increased (P< 0.05) after
the addition of 1 mM concentration of GS for 30 min, whilethe contents of UDP-GlcA and UDP-Hex decreased
(P< 0.05) (Fig. 4A). The ratio of UDP-HexN/UDP-Hex
was signiﬁcantly higher in 1 mM GS treatment for 30 min
compared with that of the controls, while the ratio of UDP-
GlcA/UDP-Hex was signiﬁcantly decreased (P< 0.05).
However, treatment with 10 mM concentration of GS for
30 min did not affect the contents of UDP-sugars.
After the 8-day-long culture period of chondrocytes, the
content of UDP-HexN was signiﬁcantly increased (P< 0.05)
after the cells were treated with 1 mM of GS for 30 min
(Fig. 4B), but no changes could be found in the content of
UDP-GlcA (Fig. 4B). Like after the 2-day culture period, addi-
tion of 10 mMof GS did not have any effect on the UDP-sugar
levels of chondrocytes (Fig. 4B). The level of UDP-GlcA had
clearly increased during the longer culture period and, as
a consequence, the ratios of the UDP-HexN/UDP-Hex and
UDP-GlcA/UDP-Hex were much higher after the 8-day
culture period than after the 2-day culture period.
The DNA content remained at a constant level when the
cells were treated with Glc, GlcN or GS for different time pe-
riods (data not shown). Thus, none of the treatments had
apparent cytotoxic effects on the cell cultures.
EFFECTS OF GLUCOSAMINE SULFATE ON GAG SYNTHESIS
AND AGGRECAN mRNA EXPRESSION
In the present study, the cells were treated with 10 mM
and 1 mM of GS in low-glucose (1.0 g/l) DMEM for 24 h.
Parallel experiments with cells from 12 different individual
animals showed that on an average GS did not increase
the GAG synthesis (Table I), or aggrecan mRNA expression
after normalization against GAPDH (Table I). However,Fig. 3. The levels of UDP-Hex (black bar), UDP-GlcA (white bar) and UDP-HexN (grey bar) analyzed by RP-HPLC/ESI-MS measurements
after the chondrocytes were treated with 1 mM of GS in low-glucose DMEM (A) for 0, 10, 20, 30, 60 and 120 min, and with 10 mM of GS
in low-glucose DMEM for 30 and 60 min (B). The experiments were performed with cell cultures from two and nine different animals,
respectively.
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(grey bar) analyzed by RP-HPLC/ESI-MS measurements after the bovine primary chondrocytes were treated with 0, 10 mM and 1 mM of GS
for 30 min following 2-day-long cell culture period (A) or 8-day-long cell culture period (B) after cell isolation. *P< 0.05. The experiments were
repeated with chondrocytes from six different animals.one individual cellular isolate (1/12) revealed increase
in GAG synthesis at 10 mM or 1 mM concentration of GS,
respectively, and increased aggrecan mRNA expression
was observed at 1 mM concentration of GS in one individual
cellular isolate (1/12). The chondrocyte cultures from four
different individual animals were also treated with 100 mM
of GS for 24 h, nevertheless, there were no changes found
in the levels of aggrecan mRNA expression (data not shown).
Discussion
The daily dose of the commercial GS product used to
treat OA patients is 1500 mg, which is equal to about
1175 mg of GlcN, or 6.5 mmol. If this amount of GlcN could
be totally and rapidly distributed in the extracellular and in-
tracellular ﬂuid of a person weighing 100 kg, the concentra-
tion of GlcN would be approximately 136 mM. However, in
practice this molar concentration is reduced due to absorp-
tion, metabolism and clearance of GlcN inside the body be-
fore reaching the synovial ﬂuid and the cartilage. Thus, the
concentration of GlcN in cartilage can never attain 100 mM
after oral administration of 1500 mg GS. In fact, the serum
GlcN concentration was shown to reach 1.9e11.5 mM after
ingestion of 1500 mg of GS15.
Nevertheless, the mechanism of action of GlcN in the
treatment of OA was initially suggested to stimulate the car-
tilage GAG synthesis because GlcN is a basic component
of cartilage GAGs. However, it must be borne in mind that
exogenous GlcN is not essential for the biosynthesis of
CS in cartilage proteoglycan. Some previous studies in vitro
and in vivo have shown that the addition of GlcN or GS to
culture medium increases the proteoglycan synthesis by
the chondrocytes19e24. However, the concentrations of
GS or GlcN used in these studies have been so high that
these concentrations cannot be reached physiologicallyin vivo after oral administration. Consequently, we investi-
gated whether exogenous Glc, GlcN or GS would enhance
CS synthesis in chondrocytes by increasing the intracellular
levels of UDP-GlcA and UDP-GalNAc. No changes in the
contents of UDP-HexN and UDP-GlcA could be detected
at either 10 or 100 mM concentration of GS in low-glucose
DMEM. It is important to notice that even when the level
of UDP-HexN increased at 1 mM concentration of GlcN or
GS, the level of UDP-GlcA appeared to remain at the con-
trol level or even decreased. This ﬁnding raises a question
whether increase in UDP-HexN can actually accelerate
GAG synthesis rate if the intracellular content of one of
the two essential components required for the GAG assem-
bly remains unchanged. Our present ﬁnding that low con-
centration of GS did not stimulate CS synthesis rate via
increased intracellular UDP-HexN and UDP-GlcA levels is
in line with the previous studies performed with mouse
and human chondrocytes25,26. It has been calculated that
the chondrocytes can produce a sufﬁcient level of GlcN
for CS synthesis from endogenous Glc, and that the exog-
enous GlcN will be diluted by the GlcN formed from endog-
enous Glc25e27. It was also determined that only 9% of
galactosamine involved in the synthesis of CS derives
from exogenous GlcN in human chondrocyte, when the
concentration of exogenous radioactively labeled GlcN
was 102 mM (at maximum) in mouse and human chondro-
cyte cultures25,26.
Interestingly, the intracellular levels of UDP-HexN and
UDP-GlcA were remarkably higher after the 8-day culture
period than after the 2-day culture period, and it seems pos-
sible that the level of UDP-GlcA can be the rate-limiting fac-
tor of GAG synthesis in newly isolated chondrocytes. Low
concentration of GS did not affect the UDP-sugar levels
either in 2- or in 8-day-old primary chondrocyte cultures.
Aggrecan is a large CS proteoglycan present in the carti-
lage, which provides osmotic resistance for the cartilage toTable I
GAG synthesis and aggrecan mRNA expression evaluated by 35S-sulfate incorporation assay and real-time quantitative RT-PCR,
respectively
Treatment Relative rate of 35S-sulfate incorporation
(meanS.D.), n¼ 12
Relative quantity of aggrecan mRNA expression
(mean S.D.), n¼ 12
Control 1.00 0.0 1.00 0.11
10 mM 1.16 0.04 1.04 0.13
1 mM 1.15 0.05 1.15 0.14
Bovine primary chondrocytes were treated with 0, 10 mM and 1 mM of GS in low-glucose DMEM for 24 h. The difference between the control
(untreated group) and treated group was evaluated with non-parametric two related-sample tests (Wilcoxon Signed Ranks Test). No signif-
icant changes were observed (P> 0.05).
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GlcN could not increase GAG synthesis or aggrecan mRNA
expression after the chondrocytes were treated with GlcN
in low- (1.0 g/l) or high-glucose (5.0 g/l) DMEM17. High
concentration of glucose in the DMEM media might have
a profound effect on the cellular viability. However, in the
present study, GS at concentration of 10 mM and 1 mM in
low-glucose DMEM did not increase GAG synthesis and
aggrecan mRNA expression in bovine primary chondrocyte.
It further conﬁrms our previous results17, and the results
performed with MC615 mouse chondrocytes25 and human
chondrocytes26, even if donor-dependent variation in re-
sponse to GS of chondrocytes has been shown23. In this
study, two out of 12 different animals showed increased
aggrecan mRNA level or GAG synthesis rate in GS-treated
cell cultures, however, there were no statistically signiﬁcant
changes when the whole data were analyzed.
In conclusion, our results indicate that exogenous, phys-
iologically relevant level of GS did not increase the intracel-
lular UDP-HexN and UDP-GlcA levels in bovine primary
chondrocytes. However, a prolonged cell culture period
could affect the intracellular UDP-HexN and UDP-GlcA
levels.
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